RecruitingPhase 4

Single and Twice-daily Dosing of Ramipril on Renal Function in Chronic Kidney Disease Patients With Reduced Ejection Fraction Heart Failure

Indonesia80 participantsStarted 2025-06-30

Plain-language summary

This study compares the effects of once-daily versus twice-daily ramipril dosing on renal function in chronic kidney disease (CKD) patients with heart failure with reduced ejection fraction (HFrEF). Outcomes include changes in plasma renin activity, malondialdehyde, interleukin-6, albuminuria, and cystatin C after 30 days of therapy.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Female or Male with age \>18 years old * Patients with a diagnosis of CKD stage 3-5 non-dialysis with low ejection fraction heart failure (ejection fraction \< 40%) Exclusion Criteria: * Receiving hemodialysis therapy * History of intolerance to ACE inhibitors * Refractory hyperkalemia * Pregnancy * History of angioedema to ACE inhibitors * Receiving sacubitril-valsartan therapy * Receiving ARB therapy * Hypotension with blood pressure \<90/60, or patients in shock.

What they're measuring

Change in Plasma Renin Activity (PRA)

Timeframe: 30 days

Change in Malondialdehyde (MDA)

Timeframe: 30 days

Change in Interleukin-6 (IL-6)

Timeframe: 30 days

Change in Albuminuria

Timeframe: 30 days

Change in Cystatin C

Timeframe: 30 days

Trial details

NCT IDNCT07259512

SponsorEvi Liliek Wulandari

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-12-31

Contact for this trial

Evi L Wulandari, MD., Internist

(+62)821-3587-2749 evililiek@staff.uns.ac.id

View on ClinicalTrials.gov More Chronic Kidney Disease trials